Humacyte (NASDAQ:HUMA) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Humacyte (NASDAQ:HUMA) posted its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06), FiscalAI reports. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.12 million.

Here are the key takeaways from Humacyte’s conference call:

• V012 Phase III interim results exceeded expectations in female dialysis patients: ATEV recipients had 91 more catheter-free days than AV fistula patients, with significantly fewer infections. Humacyte plans to file a supplemental BLA in November 2026 and is targeting a potential launch in late Q2 2027 if priority review is granted.
• Humacyte is rebuilding its SYMVESS commercial organization with vascular-surgery-focused sales personnel, a national accounts strategy, streamlined hospital value-analysis processes, and introductory pricing. At least 20 major U.S. healthcare systems are reportedly in the process of adopting the product, although meaningful benefits are expected mainly in the second half of 2026.
• The FDA accepted Humacyte’s IND for its smaller-diameter CTEV vessel in coronary artery bypass grafting, and the company expects to begin a 10-patient Phase IIa study during the current quarter. Management said initial CTEV manufacturing will not materially constrain ATEV commercial production.
• Financial results continued to reflect commercialization and manufacturing costs: second-quarter revenue was only $0.4 million, cost of goods sold reached $1.2 million including a $0.7 million inventory reserve, and net loss was $36.8 million. Cash, cash equivalents, and restricted cash totaled $80.3 million at June 30, 2026, supported in part by equity-sale proceeds.

Humacyte Stock Down 9.5%

Shares of HUMA traded down $0.07 on Wednesday, reaching $0.64. The company’s stock had a trading volume of 8,523,007 shares, compared to its average volume of 7,864,482. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.55. The stock has a market capitalization of $142.74 million, a PE ratio of -1.13 and a beta of 2.53. The firm has a fifty day moving average of $0.82 and a 200-day moving average of $0.91.

Insider Buying and Selling at Humacyte

In related news, Director Kathleen Sebelius acquired 56,818 shares of the stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average cost of $0.88 per share, with a total value of $49,999.84. Following the completion of the purchase, the director directly owned 148,025 shares in the company, valued at $130,262. This trade represents a 62.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares in the company, valued at $245,441.70. This represents a 14.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. purchased a new stake in Humacyte in the 2nd quarter worth approximately $28,000. Price T Rowe Associates Inc. MD boosted its holdings in Humacyte by 21.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after purchasing an additional 13,175 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Humacyte by 41.2% in the second quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock worth $96,000 after buying an additional 13,407 shares in the last quarter. Financial Advisors Network Inc. bought a new position in Humacyte in the 2nd quarter worth about $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Humacyte by 25.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock worth $161,000 after acquiring an additional 15,649 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Key Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Humacyte reported strong interim results from its V012 Phase 3 dialysis-access study: its acellular tissue-engineered vessel (ATEV) outperformed standard AV fistula treatment in women, including 91 additional catheter-free days and fewer infections. The company plans to submit a supplemental BLA to the FDA in the second half of 2026. Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The FDA accepted Humacyte’s IND application for a first-in-human study of its coronary tissue-engineered vessel, with a Phase 2a CABG study expected to begin in the third quarter of 2026. Symvess sales also rose to $0.4 million from $0.1 million a year earlier. Humacyte Reports Breakthrough V012 Dialysis Access Results, FDA Accepts CTEV IND, and Second-Quarter 2026 Financial Results
• Positive Sentiment: A $57.5 million public offering, approximately $14.3 million in expected 2026 cost savings, and $80.3 million in cash, cash equivalents and restricted cash improve near-term funding for commercialization and clinical development.
• Neutral Sentiment: Humacyte is strengthening its commercial organization and preparing for broader Symvess adoption, including new commercial and surgical leadership and international regulatory efforts.
• Negative Sentiment: Second-quarter adjusted results were weaker than expected: HUMA posted a loss of $0.16 per share versus the $0.10 consensus loss, while revenue of $0.41 million missed the $1.12 million estimate. Humacyte Reports Q2 Loss, Misses Revenue Estimates
• Negative Sentiment: Net loss remained substantial at $36.8 million, while cost of goods sold increased to $1.2 million, including inventory reserves and costs tied to unused production capacity. The public offering also creates potential shareholder dilution.
• Negative Sentiment: An ongoing law-firm investigation into Humacyte’s officers and directors may add headline and investor-confidence risk, although no new findings were reported in the cited update. Humacyte Investigation Continued

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. TD Cowen decreased their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. BTIG Research restated a “buy” rating and set a $2.00 price objective on shares of Humacyte in a report on Wednesday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Humacyte presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.